FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
APR-246 Sensitive: D – Preclinical
|
APR-246 Sensitive: D – Preclinical
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
MK-2206 Sensitive: D – Preclinical
|
MK-2206 Sensitive: D – Preclinical
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
tipifarnib Sensitive: D – Preclinical
|
tipifarnib Sensitive: D – Preclinical
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
erdafitinib Sensitive: D – Preclinical
|
erdafitinib Sensitive: D – Preclinical
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
INNO-406 Sensitive: D – Preclinical
|
INNO-406 Sensitive: D – Preclinical
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
|
Prostate Cancer
|
abemaciclib Sensitive: D – Preclinical
|
abemaciclib Sensitive: D – Preclinical
|